Insulin– tag –
-
Abbott’s FreeStyle Libre Offers 10-Day Real-Time Glucose Monitoring for Diabetes Patients Aged 4 and Up
Health Insider Canada Overview Abbott Laboratories' FreeStyle Libre system provides continuous glucose monitoring for diabetes patients aged four and older, utilizing a small wearable sensor and a smartphone app. This system delivers rea... -
Diabetes Devices Dominate FDA MAUDE Reports 2020-2025 with Over 50% of Adverse Events, Dexcom Largest Single Reporter
Global MedTech Expert | 10× MedTech Global Access Unknown Overview An analysis of 14.4 million FDA MAUDE adverse event reports from 2020 to 2025 reveals that diabetes-related devices account for over half of all reported events. Continuo... -
Goodman Advisory Group Invests $1.29 Million in DexCom Amidst Strong Q1 Performance, Revenue Soars 15% to $1.19 Billion
MarketBeat USA Overview Goodman Advisory Group has made a strategic investment of $1.29 million in DexCom, a leading continuous glucose monitoring (CGM) company, following DexCom's strong first-quarter earnings report. The company achiev... -
Ultrahuman Launches M2 Live Metabolic Health Platform in U.S., Integrating Abbott’s OTC Lingo CGM for Prescription-Free Glucose Tracking
PR Newswire USA Overview Ultrahuman, a smart ring manufacturer, has launched 'M2 Live,' a metabolic health platform in the U.S. that integrates data from Abbott's over-the-counter (OTC) continuous glucose monitor (CGM) 'Lingo.' Available... -
Medtronic Enhances MiniMed 780G AID System with New CGM Sensors and Launches Screenless MiniMed Flex Pump
diaTribe.org USA Overview Medtronic has introduced two new continuous glucose monitor (CGM) sensors for its MiniMed 780G automated insulin delivery (AID) system in the U.S.: the 6-day Simplera Sync and the 15-day Instinct (based on Abbot... -
FDA Clears Dexcom’s Stelo, First Over-the-Counter CGM for Non-Insulin-Using Children Aged Two and Older
FDA USA Overview The U.S. FDA has approved Dexcom's Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged two and older who do not use insulin. This expansion significantly ... -
Century Therapeutics Unveils CNTY-813 iPSC-Derived Islet Replacement Preclinical Data at ADA 2026: Demonstrates Durable Glucose Control, Immune Evasion, and Scalable Manufacturing, IND Filing Expected Q4 2026
BioSpace (via GlobeNewswire) USA Overview Century Therapeutics presented new preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the ADA 2026 Scientific Sessions. The data demonstrated durable glucose control, i... -
FDA Approves Finger-Prick Free Dexcom Stelo and Abbott Libre CGMs, Revolutionizing Metabolic Management for Non-Insulin Users
Mattioli 1885 / GoodRx USA Overview The FDA has approved continuous glucose monitoring (CGM) systems like Dexcom Stelo and Abbott's Lingo (and FreeStyle Libre series), eliminating the need for traditional finger-prick tests and marking a... -
Century Therapeutics’ iPSC-Derived Type 1 Diabetes Therapy CNTY-813 Demonstrates Durable Glucose Control and Immune Evasion in Preclinical Studies
BioSpace (Century Therapeutics) USA Overview Century Therapeutics announced groundbreaking preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, designed for Type 1 Diabetes (T1D) with Allo-Evasion™ 5.0 technology, a... -
Dexcom Reaffirms CGM Benefits for All People with Diabetes, Expands to Preventive Care with Stelo App Relaunch and Nutrisense Acquisition at ADA 2026
DexCom, Inc. USA Overview Dexcom announced favorable results from the CONNECT randomized controlled trial at ADA 2026, reaffirming CGM's benefits for non-insulin using type 2 diabetes patients. The company also launched early access to i...
